TICKERNERD
Menu
RNTXRNTXHealthcare · Biotechnology

RNTX Stock Forecast: Rein Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Aug 2026
$0.79
+0.20% on the day

The 2 Wall Street analysts covering Rein Therapeutics, Inc. hold a median 12-month price target of $6 — +656.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$70.6M
Ticker Nerd rank
37 / 100
Median analyst target
$6.00
Analysts covering
2
Total return, dividends reinvested
1W
+0.7%
1M
−6.0%
YTD
−31.6%
1Y
−31.0%
From 52W high
−57.8%
From 52W low
+11.1%
$0.71
$1.88
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RNTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Rein Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
37 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
79
Growth
78
Accruals
71
Revisions
57
Quality
30
Value
26
Volatility
26
Issuance
25
Momentum
14

Size (79): Smaller than most of the companies we track.

Momentum (14): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RNTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RNTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Oct 25Jan 26Apr 26Jul 26RNTXHigh $8.00Median $6.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $4.00Median $6.00High $8.00

The green dot is the last close — the median target sits +656.0% from it.

Recent analyst actionsNewest first

Of the 19 most recent actions, 1 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
18 Aug 2026HC Wainwright & Co.ReiteratesBuy$8.00
20 July 2026Maxim GroupInitiatesBuy$4.00
1 June 2026HC Wainwright & Co.MaintainsBuy$10 → $8.00
1 June 2026HC Wainwright & Co.MaintainsBuy—
21 Jan 2026Brookline CapitalDowngradeHold—
22 Sept 2025HC Wainwright & Co.InitiatesBuy—
19 Aug 2025Brookline CapitalDowngradeHold—
18 Apr 2024Ladenburg ThalmannMaintainsBuy$9.00 → $19
1 Dec 2023Ladenburg ThalmannUpgradeBuy$9.00
30 June 2022HC Wainwright & Co.MaintainsBuy$2.00 → $1.00
29 June 2022William BlairDowngradeMarket Perform—
5 June 2020HC Wainwright & Co.MaintainsBuy$3.00 → $2.00
31 Mar 2020H.C. WainwrightMaintainsBuy—
31 Mar 2020HC Wainwright & Co.MaintainsBuy$6.00 → $3.00
9 Apr 2019Canaccord GenuityMaintainsBuy$19 → $5.00
11 Mar 2019H.C. WainwrightInitiatesBuy—
24 July 2017Bank of AmericaInitiatesBuy—
24 July 2017Canaccord GenuityInitiatesBuy—
24 July 2017JefferiesInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RNTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

RNTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Rein Therapeutics, Inc. (RNTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.4×

Cheaper than 79% of US stocks

Price / sales
—
Price / book
−0.7×

Cheaper than 94% of US stocks

EV / EBITDA
−5.3×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−163.4%

Higher than 8% of US stocks

Return on assets
−32.1%

Higher than 13% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

RNTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RNTXRein Therapeutics, Inc.$70.6M
37
XBITXBiotech, Inc.$69.5M
32
PMVPPMV Pharmaceuticals, Inc.$70.5M
68
OSTXOS Therapies, Inc.$70.8M
29
IBIOiBio, Inc.$71.0M
26
SPROSpero Therapeutics, Inc.$68.7M
83
LONALeonaBio, Inc.$71.5M
44

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Rein Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RNTX news & analysis

Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis

GlobeNewsWire · 20 Aug 2026positive

Rein Therapeutics announced that the U.S. FDA granted Fast Track designation to LTI-03 for the treatment of idiopathic pulmonary fibrosis. The company continues to enroll patients in the RENEW Phase 2 trial, with interim data expected in the second half of 2026.

Why it matters — Fast Track designation may facilitate and expedite the development and review of LTI-03, a key pipeline asset for RNTX in a disease area with serious unmet need and no halting treatment.

Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 14 Aug 2026neutral

Rein Therapeutics, a biopharmaceutical company focused on orphan pulmonary and fibrosis indications, reported its financial results for the second quarter ended June 30, 2026, and provided a business update. The announcement was made on August 14, 2026.

Why it matters — RNTX watchers would follow this update for insight into the company's financial position and the status of its pipeline in orphan pulmonary and fibrosis indications.

Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications

GlobeNewsWire · 4 Aug 2026positive

Rein Therapeutics announced that clinical data from its first-in-human study of LTI-03 for idiopathic pulmonary fibrosis were published in the peer-reviewed journal Nature Communications. The study showed LTI-03 was safe and well-tolerated and produced measurable reductions in multiple markers of lung scarring and inflammation, with the data supporting the ongoing Phase 2 "RENEW" trial.

Why it matters — A RNTX watcher would care because publication of LTI-03's first-in-human clinical data in a prestigious journal lends external validation to the company's lead candidate as it advances into Phase 2.

FAQ

Frequently asked questions about RNTX stock

What is the RNTX stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Rein Therapeutics, Inc. have a median 12-month price target of $6, with estimates ranging from $4 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RNTX stock a buy right now?

Of the 2 analysts covering Rein Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rein Therapeutics, Inc. 37 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RNTX?

As at 22 Aug 2026, Rein Therapeutics, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (79 of 100).

Will RNTX stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +656.0% from the last close, and Ticker Nerd's factor model ranks Rein Therapeutics, Inc. 37 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RNTX stock forecast for 2030?

No analyst covering Rein Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RNTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $8 over the next 12 months.

How has RNTX stock performed over the past year?

Rein Therapeutics, Inc. returned -31.0% over the 12 months to 20 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Rein Therapeutics, Inc. do?

Rein Therapeutics Inc. is a biotechnology company dedicated to developing novel therapies for life-threatening diseases.

What is the latest news on RNTX?

The most recent item we track (GlobeNewsWire, 20 Aug 2026): "Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis". Rein Therapeutics announced that the U.S. FDA granted Fast Track designation to LTI-03 for the treatment of idiopathic pulmonary fibrosis. The company continues to enroll patients in the RENEW Phase 2 trial, with interim data expected in the second half of 2026.

Company

About Rein Therapeutics, Inc.

Rein Therapeutics Inc. is a biotechnology company dedicated to developing novel therapies for life-threatening diseases. The primary focus of the company lies in exploring advanced gene editing technologies to create treatments that address unmet clinical needs. Rein Therapeutics Inc. is heavily involved in research and development efforts, often collaborating with leading institutions and pharmaceutical firms to drive innovation in the biotech sector. Its groundbreaking work impacts various fields, particularly in genetic disorders, oncology, and infectious diseases. With headquarters based in a prominent biotech hub, Rein Therapeutics Inc. plays a significant role in the advancement of personalized medicine, delivering potentially transformative therapies to the market. As a publicly traded company, it attracts attention from a diverse range of investors and stakeholders interested in cutting-edge healthcare solutions.

CEO Dr. James Brian Windsor Ph.D. · 10 employees · United States · https://www.reintx.com